Tag Archives: head and neck cancer

August, 2018

16 August
CEL-SCI Reports Recent Data Review by the IDMC for Its Pivotal Phase 3 Head and Neck Cancer Study

VIENNA, Va.–(BUSINESS WIRE)–CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company’s pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) has completed its recent review of the Phase 3 study data. The data from all 928 enrolled …
Share

26 July
Merck’s Keytruda Significantly Improved Overall Survival as First-Line Therapy in Head and Neck Squamous Cell Carcinoma in Phase 3 Study

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), met a primary endpoint of overall survival (OS) as …
Share

16 August
FDA Removes Clinical Hold on CEL-SCI’s Phase 3 Head and Neck Cancer Trial

VIENNA, Va.–(BUSINESS WIRE)–CEL-SCI Corporation (NYSE American: CVM) today announced it has received a letter from the U.S. Food and Drug Administration (FDA) stating that the clinical hold that had been imposed on the Company’s Phase 3 cancer study with Multikine* (Leukocyte Interleukin, Inj.) has been removed and that all clinical trial activities …
Share

23 November
FDA Lifts Hold on AstraZeneca’s Head and Neck Cancer Trial

AstraZeneca today announced that the US FDA has lifted the partial clinical hold on the enrollment of new patients with head and neck squamous cell carcinoma (HNSCC) for clinical trials of durvalumab as monotherapy and in combination with tremelimumab or other potential medicines. The Phase III KESTREL trial has already …
Share
11 November
Bristol-Myers’ Opdivo Receives FDA Approval for Treatment of Squamous Cell Carcinoma of the Head and Neck

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection, for intravenous use, for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy.1 …
Share

12 October
Transgene Collaborates with Merck and Pfizer for Head and Neck Cancer Trial

Strasbourg, France, October 11, 2016, 6:00 pm CET – Transgene (Euronext Paris: TNG), a company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases, today announced it has entered a collaboration agreement with Merck, the science and technology company, and Pfizer (NYSE: PFE) under …
Share
5 October
Keytruda Ready to Help More People

Even more cancer patients might soon be benefiting from the cancer medication that helped former President Jimmy Carter. Keytruda (pembrolizumab) first started saving lives back in 2011 when a human trial led to an expedited process with the Food and Drug Administration (FDA). By 2014, this medication was approved for …
Share

21 September
Eleven Biotherapeutics Acquires Viventia Bio Creating Targeted Protein Therapeutics Oncology Company

CAMBRIDGE, Mass. & TORONTO–(BUSINESS WIRE)–Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) and Viventia Bio Inc., today announced that the two companies and the shareholders of Viventia entered into a definitive share purchase agreement under which Eleven Biotherapeutics agreed to, and simultaneously completed, the acquisition of Viventia. Under the agreement, Eleven purchased all …
Share

25 April
Bristol-Myers Squibb’s Opdivo Receives Breakthrough Therapy Designation

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Opdivo for the potential indication of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) after platinum based therapy. The Breakthrough Therapy Designation is …
Share

23 March
New Guideline Addresses Long-term Needs of Head and Neck Cancer Survivors

March 22, 2016–A new American Cancer Society guideline provides clinicians with recommendations on key areas of clinical follow-up care for survivors of head and neck cancer, a growing population numbering approximately 436,060 and accounting for 3% of all cancer survivors living in the United States. Head and neck cancer will …
Share